Drug Development Pharma - January 14, 2014
US FDA approves FARXIGA tablets for the treatment of adult patients with type 2 diabetes
AstraZeneca and Bristol-Myers Squibb Company announced the US Food and Drug Administration (FDA) approved FARXIGA™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. FARXIGA should not be used for the treatment of patients with type 1 diabetes or […]
Collaboration - January 8, 2014
Immunocore, MedImmune sign oncology research collaboration and licensing agreement
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell […]
Collaboration - January 7, 2014
Horizon and AstraZeneca partner to explore oncology-relevant genotype
Horizon Discovery and AstraZeneca have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets. This deal is the second collaboration between AstraZeneca and Horizon, and follows the announcement in April 2013 of an oncology discovery program […]
Agreement - December 20, 2013
AstraZeneca buys Bristol-Myers Squibb share of global diabetes alliance assets
According to the agreement AstraZeneca will acquire the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance for an initial consideration of $2.7 billion on completion and up to $1.4 billion in regulatory, launch and sales-related payments. Furthermore, AstraZeneca has agreed to pay various sales-related royalty payments up until 2025. In addition, AstraZeneca states […]
Pharma Business - December 9, 2013
AstraZeneca receives EU approval for vaccine
AstraZeneca has announced that the European Commission (EC) has granted marketing authorisation to its nasally administered four-strain flu vaccine Fluenz Tetra. The company said in a press release today that the approval makes the vaccine, aimed for the prevention of influenza in children and adolescents from 24 months to 18 years of age, the first […]
Uncategorized - November 20, 2013
Head of new translational research centre appointed
Karolinska Institutet and AstraZeneca has recruited Professor Bo Angelin to lead the Integrated Cardio Metabolic Centre (ICMC). Bo Angelin is a Professor of Clinical Metabolism at Karolinska Institutet and a senior consultant at the Department of Endocrinology, Metabolism & Diabetes at Karolinska University Hospital. He is an internationally renowned researcher in the field of lipid metabolism. […]
